Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Physical activity levels are low in patients with pulmonary hypertension.

González-Saiz L, Santos-Lozano A, Fiuza-Luces C, Sanz-Ayán P, Quezada-Loaiza CA, Ruiz-Casado A, Alejo LB, Flox-Camacho A, Morán M, Lucia A, Escribano-Subías P.

Ann Transl Med. 2018 Jun;6(11):205. doi: 10.21037/atm.2018.05.37.

2.

Trends in Pulmonary Hypertension Over a Period of 30 Years: Experience From a Single Referral Centre.

Quezada Loaiza CA, Velázquez Martín MT, Jiménez López-Guarch C, Ruiz Cano MJ, Navas Tejedor P, Carreira PE, Flox Camacho Á, de Pablo Gafas A, Delgado Jiménez JF, Gómez Sánchez MÁ, Escribano Subías P.

Rev Esp Cardiol (Engl Ed). 2017 Nov;70(11):915-923. doi: 10.1016/j.rec.2016.12.044. Epub 2017 Apr 26. English, Spanish.

PMID:
28454887
3.

Effects of an 8-month exercise intervention on physical capacity, NT-proBNP, physical activity levels and quality of life data in patients with pulmonary arterial hypertension by NYHA class.

Santos-Lozano A, Sanz-Ayan P, González-Saiz L, Quezada-Loaiza CA, Fiuza-Luces C, Flox-Camacho A, Munguía-Izquierdo D, Santalla A, Morán M, Escribano-Subías P, Lucia A.

Data Brief. 2017 Mar 18;12:37-41. doi: 10.1016/j.dib.2017.03.022. eCollection 2017 Jun.

4.

Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial.

González-Saiz L, Fiuza-Luces C, Sanchis-Gomar F, Santos-Lozano A, Quezada-Loaiza CA, Flox-Camacho A, Munguía-Izquierdo D, Ara I, Santalla A, Morán M, Sanz-Ayan P, Escribano-Subías P, Lucia A.

Int J Cardiol. 2017 Mar 15;231:277-283. doi: 10.1016/j.ijcard.2016.12.026.

PMID:
28189191
5.

Rationale and Design of a Randomized Controlled Trial Evaluating Whole Muscle Exercise Training Effects in Outpatients with Pulmonary Arterial Hypertension (WHOLEi+12).

Sanchis-Gomar F, González-Saiz L, Sanz-Ayan P, Fiuza-Luces C, Quezada-Loaiza CA, Flox-Camacho A, Santalla A, Munguía-Izquierdo D, Santos-Lozano A, Pareja-Galeano H, Ara I, Escribano-Subías P, Lucia A.

Cardiovasc Drugs Ther. 2015 Dec;29(6):543-550. doi: 10.1007/s10557-015-6623-4.

PMID:
26521182
6.

Predictive value of NT-proBNP combined with exercise capacity variables in pulmonary artery disease: Insights from a Spanish cohort.

Quezada-Loaiza CA, Flox-Camacho A, Santos-Lozano A, Sanchis-Gomar F, González-Saiz L, Sanz-Ayan P, Garatachea N, Lucia A, Escribano-Subías P.

Int J Cardiol. 2015;186:32-4. doi: 10.1016/j.ijcard.2015.03.155. Epub 2015 Mar 17. No abstract available.

PMID:
25804462
7.

Factors affecting the response to exercise in patients with severe pulmonary arterial hypertension.

Flox-Camacho A, Escribano-Subías P, Jiménez-López Guarch C, Fernández-Vaquero A, Martín-Ríos D, de la Calzada-Campo CS.

Arch Bronconeumol. 2011 Jan;47(1):10-6. doi: 10.1016/j.arbres.2010.07.013. Epub 2010 Dec 10. English, Spanish.

8.

[Transition from prostacyclin to bosentan in five patients with severe pulmonary hypertension: the switch is possible].

Flox Camacho A, Escribano Subías P, Tello de Meneses R, Delgado Jiménez J, Gómez Sánchez MA, Sáenz de la Calzada C.

Rev Esp Cardiol. 2006 Jul;59(7):737-9. Spanish.

9.

[Primary cardiac lymphoma: diagnosis by transjugular biopsy].

Flox Camacho A, Hernández Hernández F, Salguero Bodes R, Sánchez Pérez I, Carbonell Porras A, Tascón Pérez J.

Rev Esp Cardiol. 2003 Nov;56(11):1141-4. Spanish.

10.

[Dual left anterior descending coronary artery type IV].

Flox Camacho A, Salguero Bodes R, Hernández Hernández F.

Rev Esp Cardiol. 2003 Sep;56(9):915. Spanish. No abstract available.

Supplemental Content

Loading ...
Support Center